Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IPX054 vs CD-LD IR and CR in Parkinson's Disease
NCT00279825Phase 2Completed
- Sponsor
- Impax Laboratories
- Start
- Jan 2006
- Primary completion
- Dec 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IPX054 in Parkinson's disease (PD) (4 arms), sponsored by Impax Laboratories. Primary endpoint: Alternate tapping of keys. Started Jan 2006; status: completed.
02
Drugs
IPX054
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT00279825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00279825.